-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Zevra Therapeutics, Lowers Price Target to $18

Benzinga·11/16/2026 14:10:33
Listen to the news
Guggenheim analyst Eddie Hickman maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $23 to $18.